PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025Pharmaceutics10 citationsOpen Access

Smart Vesicle Therapeutics: Engineering Precision at the Nanoscale

View Full Paper
LBLuciano A. BenediniPMPaula V. Messina

Key Points

  • This review aims to analyze advancements in smart vesicle therapeutics used in drug delivery and precision medicine.
  • Explored design and engineering of liposomes, niosomes, polymersomes, and extracellular vesicles.
  • Discussed the tailoring of vesicle size, composition, and surface chemistry.
  • Reviewed challenges in production and clinical translation.
  • Smart vesicles demonstrate improved pharmacokinetics and reduced immunogenicity.
  • Stimuli-responsive vesicles enable targeted therapeutic action based on pH and temperature changes.
  • Integration of microfluidic manufacturing accelerates development of personalized therapeutics.

Abstract

Smart vesicle therapeutics represent a transformative frontier in nanomedicine, offering precise, biocompatible, and adaptable platforms for drug delivery and theranostic applications. This review explores recent advances in the design and engineering of liposomes, niosomes, polymersomes, and extracellular vesicles (EVs), emphasizing their capacity to integrate therapeutic and diagnostic functions within a single nanoscale system. By tailoring vesicle size, composition, and surface chemistry, researchers have achieved improved pharmacokinetics, reduced immunogenicity, and fine-tuned control of drug release. Stimuli-responsive vesicles activated by pH, temperature, and redox gradients, or external fields enable spatiotemporal regulation of therapeutic action, while hybrid bio-inspired systems merge synthetic stability with natural targeting and biocompatibility. Theranostic vesicles further enhance precision medicine by allowing real-time imaging, monitoring, and adaptive control of treatment efficacy. Despite these advances, challenges in large-scale production, reproducibility, and regulatory standardization still limit clinical translation. Emerging solutions—such as microfluidic manufacturing, artificial intelligence-guided optimization, and multimodal imaging integration—are accelerating the development of personalized, high-performance vesicular therapeutics. Altogether, smart vesicle platforms exemplify the convergence of nanotechnology, biotechnology, and clinical science, driving the next generation of precision therapies that are safer, more effective, and tailored to individual patient needs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Benedini et al. (2025) studied this question.

synapsesocial.com/papers/69401d732d562116f28f9371https://doi.org/10.3390/pharmaceutics17121588
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vesicular nanocarriers: An innovative targeted and sustained drug delivery system2026
  2. 2Engineered extracellular vesicles: From design strategies to therapeutic applications2026 · 3 citations
  3. 3Toward Smarter Drug Delivery Solutions via Liposomal Carriers, Effervescent Formulations, and Extracellular Vesicles2025 · 1 citations
  4. 4Artificially engineered vesicular vehicles for targeted therapy2024 · 3 citations
  5. 5Surface engineering of extracellular vesicles: trends, strategies, and applications in diagnosis and therapy2026